AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 24 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Using gene therapy, researchers have immunized mice against a major growth factor responsible for tumor growth.
Researchers in China at Sichuan University - Huai Medical School have developed a gene therapy vector consisting of plasmid DNA encoding for Xenopus homologous vascular endothelial growth factor (XVEGF-p) that targets tumor angiogenesis in mice. The use of xenogeneic homologous genes may hold the key for preventing and treating a number of human cancers, the research group says.
"We found that immunogene tumor therapy with a vaccine based on XVEGF was effective at both protective and therapeutic antitumor immunity in several tumor models in mice," Yu-quan Wei and coworkers said.
Wei's team performed several assays, identifying autoantibodies specific to VEGF. The autoantibodies, when purified, attacked VEGF-induced cell proliferation in vitro and angiogenesis activity in vivo, researchers said (Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen, Proceedings of the National Academy of Sciences USA, September ...
Source: HighBeam Research, New Vaccine Strategy Targets Tumor Growth Factors With Gene Therapy.